These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
466 related articles for article (PubMed ID: 29583054)
1. Sequencing of disease-modifying therapies for relapsing-remitting multiple sclerosis: a theoretical approach to optimizing treatment. Grand'Maison F; Yeung M; Morrow SA; Lee L; Emond F; Ward BJ; Laneuville P; Schecter R Curr Med Res Opin; 2018 Aug; 34(8):1419-1430. PubMed ID: 29583054 [TBL] [Abstract][Full Text] [Related]
6. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Wingerchuk DM; Carter JL Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135 [TBL] [Abstract][Full Text] [Related]
7. Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective from Qatar. Deleu D; Mesraoua B; El Khider H; Canibano B; Melikyan G; Al Hail H; Mhjob N; Bhagat A; Ibrahim F; Hanssens Y Curr Med Res Opin; 2017 Mar; 33(3):439-458. PubMed ID: 27892723 [TBL] [Abstract][Full Text] [Related]
8. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972 [TBL] [Abstract][Full Text] [Related]
9. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935 [TBL] [Abstract][Full Text] [Related]
10. Sequencing of high-efficacy disease-modifying therapies in multiple sclerosis: perspectives and approaches. Grand'Maison F; Yeung M; Morrow SA; Lee L; Emond F; Ward BJ; Laneuville P; Schecter R Neural Regen Res; 2018 Nov; 13(11):1871-1874. PubMed ID: 30233054 [TBL] [Abstract][Full Text] [Related]
11. Laquinimod for multiple sclerosis. He D; Han K; Gao X; Dong S; Chu L; Feng Z; Wu S Cochrane Database Syst Rev; 2013 Aug; (8):CD010475. PubMed ID: 23922214 [TBL] [Abstract][Full Text] [Related]
12. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis. Thomas RH; Wakefield RA Am J Health Syst Pharm; 2015 Jan; 72(1):25-38. PubMed ID: 25511835 [TBL] [Abstract][Full Text] [Related]
13. The Impact of Patient Support Programs on Adherence to Disease-Modifying Therapies of Patients with Relapsing-Remitting Multiple Sclerosis in Germany: A Non-Interventional, Prospective Study. Lenz F; Harms L Adv Ther; 2020 Jun; 37(6):2999-3009. PubMed ID: 32333326 [TBL] [Abstract][Full Text] [Related]
14. Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis. Siddiqui MK; Khurana IS; Budhia S; Hettle R; Harty G; Wong SL Curr Med Res Opin; 2018 Aug; 34(8):1361-1371. PubMed ID: 29149804 [TBL] [Abstract][Full Text] [Related]
15. Patient perspective on decisions to switch disease-modifying treatments in relapsing-remitting multiple sclerosis. Manzano A; Eskyté I; Ford HL; Pavitt SH; Potrata B; Schmierer K; Chataway J; Webb EJD; Meads D; Pepper G; Bekker HL Mult Scler Relat Disord; 2020 Nov; 46():102507. PubMed ID: 32979733 [TBL] [Abstract][Full Text] [Related]
16. Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS. Vermersch P; Oh J; Cascione M; Oreja-Guevara C; Gobbi C; Travis LH; Myhr KM; Coyle PK Mult Scler Relat Disord; 2020 Aug; 43():102158. PubMed ID: 32470857 [TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis. Bozkaya D; Livingston T; Migliaccio-Walle K; Odom T J Med Econ; 2017 Mar; 20(3):297-302. PubMed ID: 27822961 [TBL] [Abstract][Full Text] [Related]
18. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England. Maruszczak MJ; Montgomery SM; Griffiths MJ; Bergvall N; Adlard N J Med Econ; 2015; 18(11):874-85. PubMed ID: 26055952 [TBL] [Abstract][Full Text] [Related]
19. Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis. Hernandez L; Guo S; Toro-Diaz H; Carroll S; Syed Farooq SF J Med Econ; 2017 Mar; 20(3):228-238. PubMed ID: 27730845 [TBL] [Abstract][Full Text] [Related]
20. An update on new and emerging therapies for relapsing-remitting multiple sclerosis. Weinstock-Guttman B Am J Manag Care; 2013 Nov; 19(17 Suppl):s343-54. PubMed ID: 24494635 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]